Witnesses stunned as ‘fireball' meteor lights up Perth skies
The bright fireball passed through the skies about 6am on Sunday over the Central Wheatbelt, producing a brilliant yellow flash and a trail of bright green.
Witnesses were able to catch a glimpse of the early-morning meteor from Perth to the Goldfields, however, experts are yet to determine where it eventually landed.
The Perth Observatory said the astronomical sight was 'most likely an iron meteor' which had been 'orbiting within the inner Solar System'.
'To shine that brightly, the fireball — technically known as a bolide — would have been about the size of a cricket ball to a basketball,' the observatory said online.
According to Perth Observatory's Matthew Woods, the meteor would have been travelling between 16 to 60km per second, leaving behind a trail of green as the built-up friction melted.
He told 9News it was 'one hell of a meteor'.
'That was very nice … little surprise for Mother's Day,' he said.
Online, witnesses were dumbfounded by the 'spectacular' sight, with some believing it was an aeroplane.
'Never seen anything like it,' one person wrote.
'Thought someone was driving at us with high beams on at first,' said another, who watched it pass overhead from Newdegate.
A resident from Mt Magnet said they initially thought the 'huge and burning bright orange-red' light was 'the moon until it moved'.
Some thought the meteor was the Kosmos 482, a Soviet-era spacecraft that plunged back to earth more than 50 years after its failed launch to Venus.
However, Curtin University astrophysicist Steven Tingay told the ABC it was unlikely the fallen spacecraft, which likely landed over the Indian Ocean on Saturday, though European and US agencies are yet to confirm its exact location.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

ABC News
15 hours ago
- ABC News
Shot-hole borer researchers team up against tree-killing beetle in Perth
Whether it is development, mining, or dwindling groundwater, Perth's tree canopy is facing a myriad of challenges. In addition, since 2021 the city has been struggling to contain a tree-killing invasive beetle — the polyphagous shot-hole borer. The pest, which produces a deadly fungus, mainly infects exotic trees, but native varieties like melaleucas are also at risk. To quell the spread of the beetle, the state government has to date removed 4,794 trees, some from Perth's most popular green spaces — Kings Park, Hyde Park and Stirling Gardens. Last month, a national biosecurity taskforce moved from an eradication response to long-term management, worrying many working in the space, particularly those in WA's agriculture sector. Teams of researchers are working on new methods to identify, contain and kill the beetle. Funded by the WA government through the WA Agriculture Research Centre (WAARC), three major projects have received $2.17 million, paying for three years of research. Key stakeholders met this week at a symposium to hear from the funding recipients about their research so far. Theo Evans, associate professor of applied entomology at the University of Western Australia, told the symposium two trials, which commenced in September 2024, showed very promising early results. He has been trialling two methods to combat the borer — a chemical injection into infected trees and using commercially available nematodes to eat the beetle. Treena Burgess, forest pathologist and director of the Harry Butler Institute, has been overseeing several studies at Murdoch University, most notably one into the fungus the beetle produces. "A key piece of our research is going to be trying to understand how susceptible different tree species are to the fungus," Professor Burgess said. "The beetle is the vector, and the fungus is the killer of trees, and different tree species seem to be varying considerably in their susceptibility." She said some trees responded better than others to the infection. Professor Burgess said the need for information on the beetle was so acute that the universities and stakeholders would share data as it came to hand, rather than waiting for the lengthy peer-review process. "The purpose of this is to solve the problem," she said. Managing director of environmental consultancy ArborCarbon and adjunct professor at Murdoch University Paul Barber will use funding to send up an "ArborCam" to map Perth's tree coverage. ArborCarbon has already led biosecurity responses in the eastern states. "The ArborCam is special because it can collect 11 bands of data across the spectrum, and it measures things like the condition of vegetation, height, surface temperatures," Professor Barber said. ArborCarbon will use the technology to identify where the most susceptible trees are, to focus on-the-ground efforts. Professor Barber said the goal was to make the ArborCam data available online for stakeholders and researchers. Ben Phillips, professor of population biology at Curtin University, is creating models to understand how the shot-hole borer might spread, and measure how effective current methods of detection are. He has taken information from dozens of studies to create a model of population growth, and his team has discovered population growth is dependent on temperature. "Most of the eastern seaboard of Queensland is looking like a spot for the borer, particularly the area around Cairns." He said considering Perth did not even have the ideal climate, the beetle had an incredibly high growth rate. The female borer does not require a male to reproduce, and Professor Phillip's modelling showed the population could grow in Perth conditions from one to a million in just a year. All the researchers the ABC spoke to were optimistic their efforts would lead to better management tools for the dreaded pest.

Sydney Morning Herald
3 days ago
- Sydney Morning Herald
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.

The Age
3 days ago
- The Age
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.